Nominations for the 2014 award are now closed.
The Award and Lecture
Through the generous contribution of an anonymous donor, the AACR established this award in 1979 to give recognition to a young investigator on the basis of meritorious achievement in cancer research. In accordance with the wishes of the donor, the recipient must be no more than 40 years of age by the time the award is received.
The recipient of the 34th Annual AACR Award for Outstanding Achievement in Cancer Research will receive an honorarium of $5,000, presented a 50-minute lecture, and be given full support for the winner and a guest to attend the AACR Annual Meeting 2014, in San Diego, CA, USA (April 5-9, 2014.)
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
- Candidates must not be more than 40 years of age by the time the award is received. For the 2014 award, a candidate's date of birth must be on or after April 10, 1973.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves.
Nomination materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- contain a concise description of the candidate's meritorious achievement in cancer research, with the publications supporting these accomplishments directly referenced within the letter;
- contain a concise description of the impact of these accomplishments on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available through the link below and on the proposalCENTRAL website.
Program Guidelines and Nomination Instructions. Download the Adobe Acrobat Reader here.
Candidates for the award will be considered by a prestigious international Selection Committee of renowned cancer leaders appointed by the president of the AACR. The committee will consider all nominations as they have been submitted; the committee may not combine submitted nominations, add a new candidate to a submitted nomination, or otherwise make alterations to the submitted nominations. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and determination.
Selection of the award winner will be made on the basis of the candidate's meritorious achievements in cancer research. No regard will be given to race, gender, nationality, or religious or political view.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
33rd Annual Award Recipient
Roger S. Lo, M.D., Ph.D.
Assistant Professor, Department of Dermatology
University of California Los Angeles
Los Angeles, CA
Dr. Lo delivered his award lecture titled How Melanoma Escapes From BRAF Inhibition
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Tuesday, April 9, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
Dr. Roger S. Lo is recognized for his outstanding work in the field of melanoma research and for his work on the mechanisms of resistance to BRAF inhibitors.
Dr. Lo earned his bachelor's degree in biology from Stanford University, his medical doctorate and doctorate in philosophy (Howard Hughes Medical Institute) from Weill Cornell, Memorial Sloan-Kettering Cancer Center and Rockefeller University. He conducted a resiency in dermatology and postdoctoral work at UCLA Medical Center and Howard Hughes Medical Institute. His Ph.D. training and Post-doctoral training resulted in high impact manuscripts published in a series of top ranking journals including Cell, Nature, and EMBO.
With his impressive training and accomplishments, Dr. Lo then went on to become a junior faculty, where he focused his independent research in the field of melanoma. His goal ws to understand the clinical development, and more specifically, the acquired resistance observed in patients given BRAF inhibitors for the treatment of melanoma. Dr. Lo's work resulted in an early account of acquired resistance mechanisms to BRAF inhibitors, where he was able to describe the molecular mechanisms of side effects of BRAF inhibitors and the appearance of non-melanoma cutaneous squamous cell carcinomas.
Dr. Lo's work exemplifies research that is truly translational with clinically testable approaches that have resulted in better patient care. His description of the most frequent molecular mechanism of how melanoma reactivates the MAPK pathway to become resistant to single agent BRAF inhibitors is the major scientific rational for the development of combinational therapies of BRAF plus MEK inhibitors. Furthermore, based on his research, Dr. Lo predicted that the combination would decrease side effects, and this was later supported in the clinic.
Dr. Lo is currently an Assistant Professor in Residence in the Department of Medicine in the Division of Dermatology and the Department of Molecular and Medical pharmacology at the David Geffen School of Medicine at the University of California. Dr. Lo's laboratory continues to focus on melanoma research and the mechanisms of primary and acquired resistance to targeted therapies using integrated genomic technologies.